Changing the way we compound
Bridge Labs is the R&D arm of Bridge Global Health. Our first product delivers multiple drugs simultaneously through one closed-system device -- eliminating USP 797 cleanroom requirements entirely.
U.S. Utility Patent Pending
0
Cleanrooms needed
The Problem
USP 797 was written for hospitals. Not for the future of wellness.
Current sterile compounding regulations require cleanrooms, specialized pharmacists, laminar airflow hoods, and continuous environmental monitoring. For clinics delivering IV wellness therapies, this infrastructure is prohibitively expensive and operationally burdensome.
$250K+
Avg. cleanroom build-out cost
14-Day
Beyond-use dating limitation
40+ hrs
Annual staff recertification
100%
Risk of contamination with manual compounding
Before Bridge Labs
A cleanroom, a pharmacist, and a prayer
Multi-drug IV protocols required opening vials, drawing medications, and manually injecting them into IV bags -- all inside a certified ISO 5 environment. One airborne particle could mean contamination, waste, and patient risk.
After Bridge Labs
One device. Multiple drugs. Zero compounding.
Our patent pending closed-system manifold delivers multiple medications simultaneously through isolated pathways directly into the IV bag. The sterile barrier is never broken. USP 797 compounding requirements simply do not apply.
The Device
Patent pending technology, built for the point of care
Six innovations in one device that fundamentally changes how multi-drug IV therapy is delivered.
Multi-Drug Simultaneous Delivery
Introduce multiple medications through a single closed-system device directly into an IV bag -- no mixing, no compounding, no contamination risk.
USP 797 Compliant by Design
The device maintains a closed sterile pathway at every stage. Because drugs are never exposed to the environment, traditional compounding rules do not apply.
No Cleanroom Required
Eliminates the need for ISO-classified cleanrooms, laminar airflow hoods, and the six-figure capital expenditure they demand.
Point-of-Care Ready
Administer at the bedside or treatment chair. No pharmacy hold times, no batch preparation, no beyond-use dating constraints.
Dramatic Cost Reduction
Remove compounding labor, facility overhead, and waste. Clinics report projected savings of 60-80% versus outsourced compounding services.
Patent Pending Closed-System Architecture
Protected by patent pending technology. The proprietary valve and manifold design ensures each drug pathway remains isolated until the moment of infusion.
Side by Side
Traditional compounding vs. Bridge Labs
| Requirement | Traditional | Bridge Labs |
|---|---|---|
| Sterile cleanroom required | ✗ | — |
| Laminar airflow hood | ✗ | — |
| Trained compounding pharmacist | ✗ | — |
| Beyond-use dating limits | ✗ | — |
| Multi-drug simultaneous delivery | — | |
| Point-of-care administration | — | |
| Closed-system sterile pathway | — | |
| Sub-$1 per administration cost | — |
"The safest compound is the one you never have to make."
-- Bridge Labs Founding Principle
Innovation Pipeline
What's next from Bridge Labs
Multi-Drug IV Delivery Device
Closed-system manifold enabling simultaneous introduction of multiple drugs into a single IV bag without compounding.
Smart Dosing Integration
Digital dosing verification layer that confirms drug compatibility and concentration before delivery.
Connected Device Platform
IoT-enabled device tracking, usage analytics, and automated reorder integration with the Bridge supply platform.
Get Involved
See the device that makes compounding optional
Whether you operate a clinic, invest in medtech, or advise on regulatory compliance -- we want to show you what Bridge Labs has built.